RESUMEN
Lymphoma is the most common type of canine hematological malignancy where the multicentric (cMCL) form accounts for 75% of all cases. The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Here we evaluate a liquid biopsy approach based on serum Small Extracellular Vesicles enriched for exosomes (SEVs) to predict cMCL chemotherapy response. Nineteen dogs at the end of the 19-week chemotherapy protocol (8 Complete Response and 11 Progressive Disease) were evaluated for serum SEVs size, concentration and screened for 95 oncomirs. PD patients had higher SEVs concentration at the diagnosis than CR patients (P = 0.034). The ROC curve was significant for SEVs concentration to predict the response to CHOP (AUC = 0.8011, P = 0.0287). A potential molecular signature based on oncomirs from SEVs (caf-miR-205, caf-miR-222, caf-mir-20a and caf-miR-93) is proposed. To the best of our knowledge, this is the first study demonstrating the potential of a liquid biopsy based on SEVs and their miRNAs content to predict the outcome of chemotherapy for canine multicentric lymphomas.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Biomarcadores de Tumor/genética , Enfermedades de los Perros/tratamiento farmacológico , Vesículas Extracelulares/genética , Linfoma/tratamiento farmacológico , Linfoma/veterinaria , MicroARNs/genética , Animales , Biomarcadores de Tumor/sangre , Estudios de Casos y Controles , Ciclofosfamida/farmacología , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/genética , Enfermedades de los Perros/mortalidad , Perros , Doxorrubicina/farmacología , Vesículas Extracelulares/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Biopsia Líquida , Linfoma/genética , Linfoma/mortalidad , Masculino , MicroARNs/sangre , Fosfatidilinositol 3-Quinasas/sangre , Fosfatidilinositol 3-Quinasas/genética , Prednisona/farmacología , Isoformas de Proteínas/sangre , Isoformas de Proteínas/genética , Proteínas Proto-Oncogénicas c-kit/sangre , Proteínas Proto-Oncogénicas c-kit/genética , Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/sangre , Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/genética , Recurrencia , Factor de Células Madre/sangre , Factor de Células Madre/genética , Análisis de Supervivencia , Resultado del Tratamiento , Vincristina/farmacologíaRESUMEN
O epitélio olfatório (EO) é uma fonte promissora de células-tronco (CTEO) para o uso terapêutico na medicina veterinária e humana, especialmente em doenças correlacionadas com o sistema nervoso periférico (medula espinhal) e central (cérebro e tronco encefálico) , pois as CTEO possuem a capacidade de se diferenciar em células do sistema nervoso, tais como: neurônios, oligodendrócitos e astrócitos. Em humanos estas células são utilizadas em ensaios terapêuticos de doenças degenerativas como o Alzheimer e Parkinson. Em animais a casuística relativa das doenças neurodegenerativas crônicas ou agudas é baixa, devido à dificuldade de diagnóstico definitivo, desta forma o enfoque das pesquisas com terapia celular são em sua grande maioria em lesões mecânicas na medula espinhal. Devido à falta de padronização e seleção das melhores metodologias que permitam confrontação de estudos, esta revisão busca reunir as mais recentes publicações, descrevendo o potencial uso das células-tronco do epitélio olfatório em terapias celulares, discutindo os principais desafios e perspectivas futuras com enfoque na medicina veterinária.(AU)
The olfactory epithelium (OE) is a promising source of stem cells (OESC) for therapeutic use in veterinary and human medicine, especially in diseases correlated with the peripheral (spinal cord) and central (brain and brainstem) nervous system (CNS), because of its ability to differentiate into neurons, astrocytes and oligodendrocytes cells. In humans, OESC has been used primarily in therapeutic trials for degenerative diseases such as Alzheimer and Parkinson. In animals, the frequency of corresponding cases of chronic or acute neurodegenerative diseases is very low, because of the difficulty of a definitive diagnosis; thus, the focus of cell therapy research are mostly mechanical spinal cord injuries. Due to the lack of normalization and selection of the best methodologies for comparative studies, this review aims to analyze recent reports on the potential use of stem cells from the olfactory epithelium in cell therapies and to discuss the main challenges and future prospects in veterinary medicine.(AU)
